Search
Deferiprone
go.drugbank.com/drugs/DB08826ApprovedInvestigationalDeferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a...
Mifepristone
go.drugbank.com/drugs/DB00834ApprovedInvestigationalCurrently under investigation for use in psychotic depression (phase 3 trials).
Categories: Hormonal Contraceptives for Systemic UseNGX267
go.drugbank.com/drugs/DB05152InvestigationalIt is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
Troglitazone
go.drugbank.com/drugs/DB00197ApprovedWithdrawnTroglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Tienilic acid
go.drugbank.com/drugs/DB04831ApprovedWithdrawnTienilic acid, or ticrynafen, is a diuretic drug with uric acid-lowering action which was marketed for the treatment of hypertension.
Enoxolone
go.drugbank.com/drugs/DB13089InvestigationalEnoxolone (glycyrrhetic acid) has been investigated for the basic science of Apparent Mineralocorticoid Excess (AME).
Categories: Preparations for Treatment of Wounds and UlcersSodium oxybate
go.drugbank.com/drugs/DB09072ApprovedInvestigational[A251430] Due to its physiological effects, sodium oxybate is associated with a risk for substance misuse and abuse. … [A18723] For safety reasons, sodium oxybate is a controlled substance only available through a restricted program in approved countries.
Gefarnate
go.drugbank.com/drugs/DB12079InvestigationalGefarnate has been investigated for the treatment and prevention of Stomach Ulcer, Duodenal Ulcer, and Cardio-cerebrovascular Disease.
Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)Garenoxacin
go.drugbank.com/drugs/DB06160ExperimentalGarenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseLumiliximab
go.drugbank.com/drugs/DB06162InvestigationalClinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints. … It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions.